Author:
Jethava Yogesh S.,van Rhee Frits
Publisher
Springer International Publishing
Reference67 articles.
1. Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR et al (2007) A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 21(3):529–534
2. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E et al (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99(5):1745–1757
3. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C et al (1998) High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92(9):3131–3136
4. Bergsagel DE, Ross SW, Baker DT (1962) Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. V. 1-Aminocyclopentanecarboxylic acid (NSC-1026). Cancer Chemother Rep Part 1 21:101–106
5. Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ et al (1969) Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 208(9):1680–1685
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献